What is Aimovig (erenumab)?
Aimovig is a prescription medicine (erenumab) used to prevent migraine in adults. It targets the calcitonin gene-related peptide (CGRP) pathway by blocking the CGRP receptor.
Who can use Aimovig?
Aimovig is prescribed for adults for migraine prevention. The specific patient eligibility (and any limits tied to age or prior treatment) depends on the prescribing information used by the treating clinician and the country’s approved labeling.
How is Aimovig taken?
Aimovig is given as a subcutaneous injection (under the skin). Dosing and the exact injection schedule are determined by the approved product labeling and your clinician’s plan.
What side effects do people ask about with Aimovig?
Common patient questions usually focus on injection-site reactions and tolerability. Serious risks and less common effects depend on the full prescribing information, which varies by region.
Is Aimovig only available as a brand, or are there generics/biosimilars?
Because Aimovig is a biologic (a monoclonal antibody), it is not treated like a typical small-molecule generic. Whether and when biosimilars can enter depends on patent and exclusivity timing in each market.
When do Aimovig’s patents or exclusivity expire?
Patent and exclusivity timelines are market- and jurisdiction-specific. You can track reported patent events and expiration-related information for Aimovig on DrugPatentWatch.com.
See: DrugPatentWatch.com: Aimovig
What happens if Aimovig stops working?
When Aimovig does not provide enough migraine prevention, clinicians typically reassess diagnosis and triggers, adherence to the injection schedule, and overall migraine plan. Switching within CGRP-targeting options (or to other preventive therapies) is sometimes considered, depending on the individual’s response and side-effect profile.
How does Aimovig compare with other CGRP migraine preventives?
Aimovig is one CGRP-pathway option; other CGRP treatments may target different parts of the pathway (for example, some bind the ligand rather than the receptor). Choice among them often comes down to dosing schedule, patient history, insurance coverage, and tolerability.
Where to check the most accurate dosing and safety information?
For the most reliable details on administration, warnings, contraindications (if any), and side-effect reporting, consult the approved prescribing information for your country or healthcare professional.
Sources
- DrugPatentWatch.com: Aimovig